Condition
Moderate Renal Impairment
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07227922Phase 1RecruitingPrimary
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
NCT05070390Phase 1CompletedPrimary
A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
NCT02742103Phase 2Completed
A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction
NCT02128490Phase 2Completed
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
Showing all 4 trials